Innoviva (INVA)
(Delayed Data from NSDQ)
$15.26 USD
+0.27 (1.80%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.27 +0.01 (0.07%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INVA 15.26 +0.27(1.80%)
Will INVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INVA
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
Is Innoviva (INVA) Stock Undervalued Right Now?
INVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
Other News for INVA
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Innoviva: trial data for uncomplicated gonorrhea treatment presented at ESCMI
FHLC: Healthcare Dashboard For April
Analysts Offer Insights on Healthcare Companies: Lonza Group Ltd (Six Swiss: CH:LONN), Harrow Health (HROW) and Innoviva (INVA)
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva